medicina58巻3号

2021年03月発行

特集 いまさら聞けない！ 肝胆膵疾患—みなさんのギモンに答えます

肝硬変の診断と合併症に対する治療

門脈血栓症をどんな場合に疑い，最新治療を行うか

著者： 日高央¹ 魚嶋晴紀¹

所属機関： ¹北里大学医学部消化器内科学

ページ範囲：P.454 - P.457

文献概要

Question 1
門脈血栓の形成はどのような場合に起こるのですか？

参考文献

1）DeLeve LD, et al；American Association for the Study Liver Diseases：Vascular disorders of the liver. Hepatology 49：1729-1764, 2009

2）European Association for the Study of the Liver：EASL clinical practice guidelines；Vascular diseases of the liver. J Hepatol 64：179-202, 2016

portal vein thrombosis in virus-related cirrhosis；Predictive factors and long-term outcomes. Am J Gastroenterol 108：568-574, 2013

4）Amitrano L, et al：Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 40：736-741, 2004

5）Francoz C, et al：Splanchnic vein thrombosis in candidates for liver transplantation；Usefulness of screening and anticoagulation. Gut 54：691-697, 2005

6）Lisman T, et al：Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats. J Hepatol 59：358-366, 2013

7）de Franchis R；Baveno VI Faculty：Expanding consensus in portal hypertension；Report of the Baveno VI Consensus Workshop；Stratifying risk and individualizing care for portal hypertension. J Hepatol 63：743-752, 2015

8）Hidaka H, et al：Antithrombin Ⅲ administration for portal vein thrombosis in patients with liver disease；A randomized double-blind controlled trial. Hepatol Res 48：E107-E116, 2018

9）Villa E, et al：Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143：1253-1260.e1-4, 2012

10）Amitrano L, et al：Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol 102：2464-2470, 2007

11）Nomura H, et al：Negative predictive value of D-dimer for diagnosis of venous thromboembolism. Int J Hematol 87：250-255, 2008

12）馬場俊之，他：門脈血栓症を合併した肝硬変に対するダナパロイドナトリウムの有用性．日門亢会誌23：41-49, 2017

13）Amitrano L, et al：Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 44：448-451, 2010

14）Delgado MG, et al：Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 10：776-783, 2012

15）Linkins LA, et al：Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism；A meta-analysis. Ann Intern Med 139：893-900, 2003

16）Hanafy AS, et al：Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol 113：86-91, 2019

17）Nagaoki Y, et al：Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res 48：51-58, 2018